Adjunctive fluvoxamine inhibits clozapine-related weight gain and metabolic disturbances

Journal of Clinical Psychiatry

Volumn 65, Issue 6, 2004, Pages 766-771

  Lu, Mong Liang ^a   Lane, Hsien Yuan ^b   Lin, Shih Ku ^c   Chen, Kun Po ^c   Chang, Wen Ho ^d  

^a TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^b CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^c TAIPEI CITY PSYCHIATRIC CENTER   (Taiwan)

^d TZU CHI UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; CLOZAPINE; DRUG DERIVATIVE; FLUVOXAMINE; NEUROLEPTIC AGENT; NORCLOZAPINE; SEROTONIN UPTAKE INHIBITOR; TRIACYLGLYCEROL;

ADOLESCENT; ADULT; ARTICLE; BLOOD; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG COMBINATION; DRUG EFFECT; DRUG INTERACTION; DRUG MONITORING; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; HYPERLIPIDEMIA; MALE; METABOLISM; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL; WEIGHT GAIN;

ADOLESCENT; ADULT; ANTIPSYCHOTIC AGENTS; BLOOD GLUCOSE; CHOLESTEROL; CLOZAPINE; DRUG INTERACTIONS; DRUG MONITORING; DRUG THERAPY, COMBINATION; FEMALE; FLUVOXAMINE; HUMANS; HYPERGLYCEMIA; HYPERLIPIDEMIAS; MALE; MIDDLE AGED; SEROTONIN UPTAKE INHIBITORS; TRIGLYCERIDES; WEIGHT GAIN;

EID: 4344601255     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v65n0607     Document Type: Article

References (70)

1. Kane J, Honigfeld G, Singer J, et al. Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988;45:789-796 (Pubitemid 18222922)
2. Rosenheck R, Cramer J, Xu W, et al. A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia. N Engl J Med 1997;337:809-815
3. Meltzer HY, Cola PA. The pharmacoeconomics of clozapine: a review. J Clin Psychiatry 1994;55(9,suppl B):161-165 (Pubitemid 24353044)
4. Perry PJ, Miller DD, Arndt SV, et al. Clozapine and norclozapine plasma concentrations and clinical response of treatment-refractory schizophrenic patients. Am J Psychiatry 1991;148:231-235
5. Lane HY, Chang WH. Clozapine versus risperidone in treatment-refractory schizophrenia: possible impact of dosing strategies [letter]. J Clin Psychiatry 1999;60:487-488 (Pubitemid 29369807)
6. Buchanan RW. Clozapine: efficacy and safety. Schizophr Bull 1995;21:579-591
7. Jann MW, Grimsley SR, Gray EC, et al. Pharmacokinetics and pharmacodynamics of clozapine. Clin Pharmacokinet 1993;24:161-176 (Pubitemid 23052199)
8. Lieberman JA. Maximizing clozapine therapy: managing side effects. J Clin Psychiatry 1998;59(suppl 3):38-43 (Pubitemid 28196369)
9. Allison DB, Mentore JL, Heo M, et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 1999;156:1686-1696 (Pubitemid 29517559)
10. Gaulin BD, Markowitz JS, Caley CF, et al. Clozapine-associated elevation in serum triglycerides. Am J Psychiatry 1999;156:1270-1272 (Pubitemid 29374891)
11. Henderson DC, Cagliero E, Gray C, et al. Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: a five-year naturalistic study. Am J Psychiatry 2000;157:975-981 (Pubitemid 30412350)
12. Lindenmayer JP, Nathan AM, Smith RC. Hyperglycemia associated with the use of atypical antipsychotics. J Clin Psychiatry 2001;62(suppl 23):30-38 (Pubitemid 32952692)
13. Popli AP, Konicki PE, Jurjus GJ, et al. Clozapine and associated diabetes mellitus. J Clin Psychiatry 1997;58:108-111 (Pubitemid 27149251)
14. Hagg S, Joelsson L, Mjorndal T, et al. Prevalence of diabetes and impaired glucose tolerance in patients treated with clozapine compared with patients treated with conventional depot neuroleptic medications. J Clin Psychiatry 1998;59:294-299 (Pubitemid 28353977)
15. Allison DB, Fontaine KR, Heo M, et al. The distribution of body mass index among individuals with and without schizophrenia. J Clin Psychiatry 1999;60:215-220 (Pubitemid 29193917)
16. Mukherjee S, Decina P, Bocola V, et al. Diabetes mellitus in schizophrenic patients. Compr Psychiatry 1996;37:68-73 (Pubitemid 26024880)
17. Perkins DO. Predictors of noncompliance in patients with schizophrenia. J Clin Psychiatry 2002;63:1121-1128 (Pubitemid 36084056)
18. Lane HY, Jann MW, Chang YC, et al. Repeated ingestion of grapefruit juice does not alter clozapine's steady-state plasma levels, effectiveness, and tolerability. J Clin Psychiatry 2001;62:812-817 (Pubitemid 33104668)
19. Correa N, Opler LA, Kay SR, et al. Amantadine in the treatment of neuroendocrine side effects of neuroleptics. J Clin Psychopharmacol 1987;7:91-95 (Pubitemid 17053370)
20. Floris M, Lejeune J, Deberdt W. Effect of amantadine on weight gain during olanzapine treatment. Eur Neuropsychopharmacol 2001;11:181-182 (Pubitemid 32335561)
21. Gracious BL, Krysiak TE, Youngstrom EA. Amantadine treatment of psychotropic-induced weight gain in children and adolescents: case series. J Child Adolesc Psychopharmacol 2002;12:249-257 (Pubitemid 35191352)
22. Baptista T, Hernandez L, Prieto LA, et al. Metformin in obesity associated with antipsychotic drug administration: a pilot study [letter]. J Clin Psychiatry 2001;62:653-655 (Pubitemid 32848172)
23. Morrison JA, Cottingham EM, Barton BA. Metformin for weight loss in pediatric patients taking psychotropic drugs. Am J Psychiatry 2002;159:655-657 (Pubitemid 34274950)
24. Sacchetti E, Guarneri L, Bravi D. H2 antagonist nizatidine may control olanzapine-associated weight gain in schizophrenic patients. Biol Psychiatry 2000;48:167-168 (Pubitemid 30618806)
25. Anghelescu I, Klawe C, Benkert O. Orlistat in the treatment of psychopharmacologically induced weight gain [letter]. J Clin Psychopharmacol 2000;20:716-717 (Pubitemid 30953823)
26. Dursun SM, Devarajan S. Clozapine weight gain, plus topiramate weight loss [letter]. Can J Psychiatry 2000;45:198 (Pubitemid 30238116)
27. Levy E, Margolese HC, Chouinard G. Topiramate produced weight loss following olanzapine-induced weight gain in schizophrenia [letter]. J Clin Psychiatry 2002;63:1045 (Pubitemid 35388066)
28. Centorrino F, Baldessarini RJ, Frankenburg FR, et al. Serum levels of clozapine and norclozapine in patients treated with selective serotonin reuptake inhibitors. Am J Psychiatry 1996;153:820-822 (Pubitemid 26171680)
29. Chong SA, Remington G. Clozapine augmentation: safety and efficacy. Schizophr Bull 2000;26:421-440 (Pubitemid 30423219)
30. Buckley P, Miller A, Olsen J, et al. When symptoms persist: clozapine augmentation strategies. Schizophr Bull 2001;27:615-628 (Pubitemid 34093248)
31. Jefferson JW. Drug interactions: friend or foe? J Clin Psychiatry 1998;59(suppl 4):37-47
32. Greenblatt DJ, von Moltke LL, Harmatz JS, et al. Drug interactions with newer antidepressants: role of human cytochromes P450. J Clin Psychiatry 1998;59(suppl 15):19-27 (Pubitemid 28467474)
33. Chang WH, Augustin B, Lane HY, et al. In-vitro and in-vivo evaluation of the drug-drug interaction between fluvoxamine and clozapine. Psychopharmacology (Berl) 1999;145:91-98 (Pubitemid 29339767)
34. Olesen OV, Linnet K. Fluvoxamine-clozapine drug interaction: inhibition in vitro of five cytochrome P450 isoforms involved in clozapine metabolism. J Clin Psychopharmacol 2000;20:35-42 (Pubitemid 30056351)
35. Szegedi A, Anghelescu I, Wiesner J, et al. Addition of low-dose fluvoxamine to low-dose clozapine monotherapy in schizophrenia: drug monitoring and tolerability data from a prospective clinical trial. Pharmacopsychiatry 1999;32:148-153 (Pubitemid 29434281)
36. Lammers CH, Deuschle M, Weigmann H, et al. Coadministration of clozapine and fluvoxamine in psychotic patients: clinical experience. Pharmacopsychiatry 1999;32:76-77 (Pubitemid 29197554)
37. Lu ML, Lane HY, Chen KP, et al. Fluvoxamine reduces the clozapine dosage needed in refractory schizophrenic patients. J Clin Psychiatry 2000;61:594-599 (Pubitemid 30677975)
38. Spina E, Avenoso A, Facciola G, et al. Relationship between plasma concentrations of clozapine and norclozapine and therapeutic response in patients with schizophrenia resistant to conventional neuroleptics. Psychopharmacology (Berl) 2000;148:83-89 (Pubitemid 30062476)
39. Gerson SL, Arce C, Meltzer HY. N-desmethylclozapine: a clozapine metabolite that suppresses haemopoiesis. Br J Haematol 1994;86:555-561 (Pubitemid 24199044)
40. Mauri MC, Rudelli R, Bravin S, et al. Clozapine metabolism rate as a possible index of drug-induced granulocytopenia. Psychopharmacology (Berl) 1998;137:341-344 (Pubitemid 28305369)
41. Deliliers GL, Servida F, Lamorte G, et al. In vitro effect of clozapine on hemopoietic progenitor cells. Haematologica 1998;83:882-889
42. Kuoppamaki M, Syvalahti E, Hietala J. Clozapine and N-desmethylclozapine are potent 5-HT1C receptor antagonists. Eur J Pharmacol 1993;245:179-182 (Pubitemid 23115053)
43. Tecott LH, Sun LM, Akana SF, et al. Eating disorder and epilepsy in mice lacking 5-HT2c serotonin receptors. Nature 1995;374:542-546
44. Lu ML, Lane HY, Jann MW, et al. Dosing strategies of clozapine- fluvoxamine cotreatment. J Clin Psychopharmacol 2002;22:626-628 (Pubitemid 35416792)
45. Hinze-Selch D, Deuschle M, Weber B, et al. Effect of coadministration of clozapine and fluvoxamine versus clozapine monotherapy on blood cell counts, plasma levels of cytokines and body weight. Psychopharmacology (Berl) 2000;149:163-169 (Pubitemid 30238954)
46. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Washington, DC, American Psychiatric Association; 1994
47. Lane HY, Su KP, Chang WH, et al. Elevated plasma clozapine concentrations after phenobarbital discontinuation [letter]. J Clin Psychiatry 1998;59:131-133 (Pubitemid 28150861)
48. American Diabetes Association. Screening for type 2 diabetes. Diabetes Care 2000;23(suppl 1):S20-S23 (Pubitemid 30026986)
49. Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). JAMA 1993;269:3015-3023
50. Lingjaerde O, Ahlfors UG, Bech P, et al. The UKU Side Effect Rating Scale: a new comprehensive rating scale for psychotropic drugs and cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand Suppl 1987;334:1-100 (Pubitemid 17115352)
51. Guy W. ECDEU Assessment Manual for Psychopharmacology. US Dept Health, Education, and Welfare publication (ADM) 76-338. Rockville, Md: National Institute of Mental Health; 1976; 218-222
52. Lane HY, Chang YC, Chang WH, et al. Effects of gender and age on plasma levels of clozapine and its metabolites: analyzed by critical statistics. J Clin Psychiatry 1999;60:36-40 (Pubitemid 29069884)
53. Wieczorek I, Schulz C, Jarry H, et al. The effects of the selective serotonin reuptake-inhibitor fluvoxamine on body weight in Zucker rats are mediated by corticotropin-releasing hormone. Int J Obes Relat Metab Disord 2001;25:1566-1569 (Pubitemid 32977879)
54. Abell CA, Farquhar DL, Galloway SM, et al. Placebo controlled double-blind trial of fluvoxamine maleate in the obese. J Psychosom Res 1986;30:143-146 (Pubitemid 16119444)
55. Fernstrom MH, Massoudi M, Kupfer DJ. Fluvoxamine and weight loss [letter]. Biol Psychiatry 1988;24:948-949
56. de Zwaan M, Nutzinger DO. Effect of fluvoxamine on total serum cholesterol levels during weight reduction. J Clin Psychiatry 1996;57:346-348 (Pubitemid 26277887)
57. Umbricht DS, Pollack S, Kane JM. Clozapine and weight gain. J Clin Psychiatry 1994;55(9, suppl B):157-160 (Pubitemid 24353043)
58. Henderson DC. Clozapine: diabetes mellitus, weight gain, and lipid abnormalities. J Clin Psychiatry 2001;62(suppl 23):39-44 (Pubitemid 32952693)
59. Poyurovsky M, Pashinian A, Gil-Ad I, et al. Olanzapine-induced weight gain in patients with first-episode schizophrenia: a double-blind, placebo-controlled study of fluoxetine addition. Am J Psychiatry 2002;159:1058-1060 (Pubitemid 34586958)
60. Bustillo JR, Lauriello J, Parker K, et al. Treatment of weight gain with fluoxetine in olanzapine-treated schizophrenic outpatients. Neuropsychopharmacology 2003;28:527-529
61. Pirmohamed M, Williams D, Madden S, et al. Metabolism and bioactivation of clozapine by human liver in vitro. J Pharmacol Exp Ther 1995;272:984-990
62. Linnet K, Olesen OV. Metabolism of clozapine by c-DNA expressed human cytochrome P450 enzymes. Drug Metab Dispos 1997;25:1379-1382 (Pubitemid 28010923)
63. Prior TI, Chue PS, Tibbo P, et al. Drug metabolism and atypical antipsychotics. Eur Neuropsychopharmacol 1999;9:301-309 (Pubitemid 29253781)
64. Wirshing DA, Boyd JA, Meng LR, et al. The effects of novel antipsychotics on glucose and lipid levels. J Clin Psychiatry 2002;63:856-865 (Pubitemid 35231725)
65. Melkersson KI, Hulting AL, Brismar KE. Different influences of classical antipsychotics and clozapine on glucose-insulin homeostasis in patients with schizophrenia or related psychoses. J Clin Psychiatry 1999;60:783-791
66. Melkersson KI, Hulting AL. Insulin and leptin levels in patients with schizophrenia or related psychoses: a comparison between different antipsychotic agents. Psychopharmacology (Berl) 2001;154:205-212 (Pubitemid 32186506)
67. Frankenburg FR, Zanarini MC, Kando J, et al. Clozapine and body mass change. Biol Psychiatry 1998;43:520-524 (Pubitemid 28161297)
68. Melkersson KI, Dahl ML. Relationship between levels of insulin or triglycerides and serum concentrations of the atypical antipsychotics clozapine and olanzapine in patients on treatment with therapeutic doses. Psychopharmacology (Berl) 2003;170:157-166 (Pubitemid 37421527)
69. Chong SA, Tan CH, Lee HS. Worsening of psychosis with clozapine and selective serotonin reuptake inhibitor combination: two case reports. J Clin Psychopharmacol 1997;17:68-69 (Pubitemid 27047277)
70. Tie H, Walker BD, Singleton CB, et al. Clozapine and sudden death. J Clin Psychopharmacol 2001;21:630-632 (Pubitemid 33116673)